Ebers GC. Environmental factors and MS. Lancet Neurology. 2008;7(3):268-277.
Goodin DS, Frohman EM, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002 Jan 22;58(2):169-178.
Multiple sclerosis (MS). EBSCO DynaMed Plus website. Available at:https://www.dynamed.com/topics/dmp~AN~T116285/Multiple-sclerosis-MS. Updated July 23, 2018. Accessed September 26, 2018.
NINDS multiple sclerosis information page. National Institute of Neurological Disorders and Stroke website. Available at: https://www.ninds.nih.gov/Disorders/All-Disorders/Multiple-Sclerosis-Information-Page. Accessed September 27, 2018.
Nolan D, Castley A, Tschochner M, et al. Contributions of vitamin D response elements and HLA promoters to multiple sclerosis risk. Neurology. 2012;79(6):538-546.
What is MS? National Multiple Sclerosis Society website. Available at: http://www.nationalmssociety.org/What-is-MS. Accessed September 13, 2016.
11/9/2015 DynaMed Plus Systematic Literature Surveillancehttp://www.dynamed.com/topics/dmp~AN~T116285/Multiple-sclerosis-MS: Kuo CF, Grainge MJ, Valdes AM, et al. Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families. JAMA Intern Med. 2015;175(9):1518-1526.